key: cord-1000730-slxbxmg8
authors: Iavarone, Massimo; Sangiovanni, Angelo; Carrafiello, Gianpaolo; Rossi, Giorgio; Lampertico, Pietro
title: Management of hepatocellular carcinoma in the time of COVID-19
date: 2020-04-21
journal: Annals of oncology : official journal of the European Society for Medical Oncology
DOI: 10.1016/j.annonc.2020.04.007
sha: e58b30f33aece11b9aa70128cb967ff914c04358
doc_id: 1000730
cord_uid: slxbxmg8

nan

However, we should also consider the collateral damage it brings to the systems of care on which our patients depend, including interruption and delay the schedule of HCC screening, treatments, and follow-up. Currently, Italy is facing the COVID-19 pandemic as other Western countries, with clinical activities being reduced and postponed to minimize the risk of transmission and to have all health personnel involved in facing the emergency.

We agree that more intensive attention should be paid to patients with cancer during the COVID-19 crisis, both for reducing the risk of SARS-CoV-2 infection and ensuring appropriate cancer patient management programs. In our center, all HCC cases are managed following EASL guidelines and the BCLC staging system based on discussion from multidisciplinary meetings. 2, 3 To tackle the COVID-19 crisis by reducing as low as possible the risk of patients' exposure to SARS-CoV-2 and spreading of the infection within the hospital, we modified the management algorithm as follows:

1. Telemedicine by video-call has been preferred to face-to-face visits.

2. The weekly multidisciplinary meetings are conducted by conference calls, sharing images online to reduce the risk for health-care operators without delaying decisions.

3. Indications for liver transplantation (LT) has not changed, although management follows a recently published algorithm. 4 In summary, we have reserved LT for patients with high risk of drop-out due to progression of HCC. This decision has been made not only because of the shortage of ICU beds availability, but also following the dramatic reduction in the donor pool.

4. Moreover, to reduce the risk of disease progression during the waiting period, we encouraged locoregional treatment (LRT) as bridge treatment to LT, whenever possible. 9. Imaging techniques performed for diagnosis or staging are revised via the intranet, telemedicine or after courier delivery. As far as patients who receive any treatment, radiological follow-up is scheduled as usual, but postponed up to three months, in elderly patients and in those with comorbidities.

According to these modifications in our HCC management, we compared our performance between 24 th February and 20 th March 2020 to those in the same time-frame in 2019 (Table 1 ). In summary, the HCC treatments for 42 patients were scheduled with a delay of ≥2 months in only 11 (26%) patients: 2 TA, 4 TACE, 3 TARE, and 2 systemic therapies. TAs were performed instead of preplanned surgical resection in 3 patients.

As the pandemic evolves, our approach to HCC management will be reviewed and our procedures updated. However, we believe that many of these changes implemented today to face this crisis will remain useful in managing any future emergencies. period in 2019 was compared to a 4-week period in 2020. 

Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Coronavirus Disease 2019 and Transplantation: a view from the inside

How to handle a COVID-19 patient in the angiographic suite